{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["65(3)"],"submitter":["Chen DF"],"pubmed_abstract":["<h4>Purpose</h4>To characterize the natural history of normal-tension glaucoma (NTG) in Chinese patients.<h4>Methods</h4>The prospective observational cohort study included patients with untreated NTG with a minimum follow-up of 2 years. Functional progression was defined by visual field (VF) deterioration, while structural progression was characterized by thinning of the retinal nerve fiber layer (RNFL) or ganglion cell inner plexiform layer (GCIPL).<h4>Results</h4>Among 84 participants (mean age, 60.5 years; mean deviation, -5.01 decibels [dB]) with newly diagnosed NTG followed for an average of 69.7 months, 63.1% progressed during the observation period. Specifically, 29.8% progressed by VF, and 48.8% progressed by either RNFL or GCIPL. In Cox proportional hazards analysis, disc hemorrhage (hazard ratio [HR], 2.82; 95% confidence interval [CI], 1.48-5.35), female gender (HR, 1.98; 95% CI, 1.08-3.62), and mean IOP during the follow-up period (HR, 1.14 per mm Hg; 95% CI, 1.00-1.31) were significant predictors of glaucomatous progression. Additionally, longer axial length (AL; HR, 0.57 per millimeter; 95% CI, 0.35-0.94) was protective against VF progression faster than -0.50 dB/y, and higher minimum diastolic blood pressure (DBP; HR, 0.96 per mm Hg; 95% CI, 0.92-1.00) was protective against structural progression.<h4>Conclusions</h4>Nearly two-thirds of untreated Chinese patients with NTG progressed over an average follow-up of 70 months by VF, RNFL, or GCIPL. Disc hemorrhage, female gender, higher mean IOP, shorter AL, and lower minimum DBP were significant predictors for disease progression."],"journal":["Investigative ophthalmology & visual science"],"pagination":["28"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10959195"],"repository":["biostudies-literature"],"pubmed_title":["Natural History and Risk Factors for Glaucoma Progression in Chinese Patients With Normal-Tension Glaucoma."],"pmcid":["PMC10959195"],"pubmed_authors":["Wang N","Lu X","Zuo J","Wang C","Liang Y","Si Y","Zhou W","Huang Q","Cheng G","Leung DYL","Chen DF","Friedman DS"],"additional_accession":[]},"is_claimable":false,"name":"Natural History and Risk Factors for Glaucoma Progression in Chinese Patients With Normal-Tension Glaucoma.","description":"<h4>Purpose</h4>To characterize the natural history of normal-tension glaucoma (NTG) in Chinese patients.<h4>Methods</h4>The prospective observational cohort study included patients with untreated NTG with a minimum follow-up of 2 years. Functional progression was defined by visual field (VF) deterioration, while structural progression was characterized by thinning of the retinal nerve fiber layer (RNFL) or ganglion cell inner plexiform layer (GCIPL).<h4>Results</h4>Among 84 participants (mean age, 60.5 years; mean deviation, -5.01 decibels [dB]) with newly diagnosed NTG followed for an average of 69.7 months, 63.1% progressed during the observation period. Specifically, 29.8% progressed by VF, and 48.8% progressed by either RNFL or GCIPL. In Cox proportional hazards analysis, disc hemorrhage (hazard ratio [HR], 2.82; 95% confidence interval [CI], 1.48-5.35), female gender (HR, 1.98; 95% CI, 1.08-3.62), and mean IOP during the follow-up period (HR, 1.14 per mm Hg; 95% CI, 1.00-1.31) were significant predictors of glaucomatous progression. Additionally, longer axial length (AL; HR, 0.57 per millimeter; 95% CI, 0.35-0.94) was protective against VF progression faster than -0.50 dB/y, and higher minimum diastolic blood pressure (DBP; HR, 0.96 per mm Hg; 95% CI, 0.92-1.00) was protective against structural progression.<h4>Conclusions</h4>Nearly two-thirds of untreated Chinese patients with NTG progressed over an average follow-up of 70 months by VF, RNFL, or GCIPL. Disc hemorrhage, female gender, higher mean IOP, shorter AL, and lower minimum DBP were significant predictors for disease progression.","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Mar","modification":"2025-04-22T13:01:17.012Z","creation":"2025-04-06T00:28:01.663Z"},"accession":"S-EPMC10959195","cross_references":{"pubmed":["38506850"],"doi":["10.1167/iovs.65.3.28"]}}